Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -110.37 | 3.30 | — | 5.11 | 9.81 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.41 | 22.09 | 10.38 | 2.34 | 1.94 | 4.79 | 3.42 | 1.56 | 5.37 | 10.42 | 14.01 | 10.54 | 23.94 | 26.09 | 73.80 | 21.58 | 93.04 | 78.45 | 117.78 | 157.76 | 5.94 |
| — | +361.3% | +203.6% | +50.1% | -63.9% | -54.0% | -75.6% | -85.2% | -77.6% | -60.1% | -81.0% | -51.2% | -74.3% | -66.7% | -37.3% | -86.3% | +1467.3% | +1889.7% | +1247.7% | +9357.0% | — | |
| P/B Ratio | 42.77 | 229.41 | 83.21 | 27.22 | — | — | 11.16 | 3.79 | 7.65 | 46.27 | 8.42 | 4.31 | 2.64 | 2.43 | 2.12 | 2.24 | 1.73 | 1.25 | 1.38 | 1.79 | 1.29 |
| — | — | +645.6% | +617.6% | — | — | +32.5% | -12.0% | +189.7% | +1802.3% | +296.7% | +92.2% | +52.3% | +94.0% | +53.6% | +25.3% | +34.0% | +2.1% | +34.2% | +77.4% | +73.5% | |
| P/FCF | 76.66 | — | — | 2.58 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 25.42 | 42.61 | — | 3.95 | 5.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 26.71 | 8.62 | — | 3.84 | 5.51 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.0% | -90.8% | 97.6% | 199.8% | 58.8% | -69.9% | -48.3% | 1.2% | -40.6% | -282.8% | -416.0% | -272.3% | -830.6% | -851.5% | -2444.2% | -243.3% | -1606.4% | -1614.1% | -2221.2% | -2548.5% | -6.4% |
| — | -29.8% | +302.2% | +16335.7% | +244.9% | +75.3% | +88.4% | +100.4% | +95.1% | +66.8% | +83.0% | -11.9% | +48.3% | +47.2% | -10.0% | +90.5% | -25112.6% | -10383.9% | -1830.9% | -4078.6% | — | |
| Operating Margin | 20.4% | 51.5% | -135.5% | 61.8% | 45.5% | -117.5% | -99.2% | -22.4% | -75.8% | -367.5% | -587.8% | -467.9% | -1137.2% | -1160.2% | -3231.5% | -381.5% | -2291.8% | -2286.1% | -3273.1% | -3081.8% | -32.4% |
| — | +143.8% | -36.7% | +375.5% | +160.0% | +68.0% | +83.1% | +95.2% | +93.3% | +68.3% | +81.8% | -22.6% | +50.4% | +49.2% | +1.3% | +87.6% | -6979.1% | -128687.2% | -1904.9% | -5645.3% | — | |
| Net Margin | -5.6% | 668.9% | -206.9% | 45.8% | 19.8% | -173.5% | -141.6% | -50.5% | -109.4% | -425.3% | -612.0% | -468.8% | -1124.4% | -1151.6% | -3220.9% | -388.0% | -2591.0% | -2677.1% | -3737.6% | -3218.4% | -31.9% |
| — | +485.5% | -46.1% | +190.7% | +118.1% | +59.2% | +76.9% | +89.2% | +90.3% | +63.1% | +81.0% | -20.8% | +56.6% | +57.0% | +13.8% | +87.9% | -8019.8% | -187282.8% | -2214.4% | -5839.3% | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -24.5% | 1576.2% | -211.7% | 1273.1% | — | — | -75.0% | -28.1% | -69.7% | -161.9% | -64.7% | -40.5% | -27.8% | -23.5% | -19.5% | -9.8% | -11.5% | -10.3% | -10.6% | -8.8% | -1.7% |
| — | — | -182.3% | +4636.2% | — | — | -16.0% | +30.7% | -151.2% | -589.6% | -231.1% | -313.7% | -141.1% | -128.9% | -85.1% | -11.3% | -564.4% | -9070.3% | -126.2% | -198.9% | +73.0% | |
| ROA | -3.1% | 56.9% | -15.2% | 13.8% | 4.4% | -10.2% | -8.7% | -4.5% | -7.1% | -11.2% | -10.2% | -9.0% | -7.4% | -7.5% | -7.6% | -4.3% | -5.5% | -5.3% | -5.7% | -6.1% | -1.6% |
| — | +657.4% | -75.5% | +410.2% | +161.5% | +8.9% | +15.2% | +50.4% | +3.9% | -50.2% | -34.4% | -109.0% | -35.5% | -40.7% | -33.2% | +29.5% | -249.9% | -4979.2% | -28.0% | -172.6% | +74.1% | |
| ROIC | 55.1% | — | -39.6% | 33.8% | 39.1% | — | — | — | — | -21.9% | -16.2% | -34.7% | -23.2% | -24.3% | -20.4% | -8.7% | -9.0% | -9.5% | -71.5% | — | -7.1% |
| — | — | — | — | — | — | — | — | — | +10.1% | +20.9% | -299.8% | -156.4% | -155.4% | +71.4% | — | -26.9% | -1952.0% | -535.2% | — | +38.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.38 | 1.24 | 21.76 | 7.81 | — | — | 0.46 | 0.23 | 0.20 | 1.72 | 6.86 | 0.20 | 0.15 | 0.13 | 0.10 | 0.07 | 0.07 | 0.07 | 0.06 | 0.06 | 0.05 |
| — | — | +4652.8% | +3351.6% | — | — | -93.3% | +11.9% | +29.1% | +1265.2% | +6774.2% | +172.5% | +112.0% | +89.1% | +60.2% | +26.2% | +30.9% | +23.4% | +11968.0% | +6720.4% | +2123.9% | |
| Debt / EBITDA | 0.28 | 0.97 | — | 4.31 | 9.81 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.07 | 5.61 | 7.58 | 9.07 | 8.68 | 8.22 | 8.25 | 9.51 | 10.23 | 9.09 | 11.53 | 10.87 | 10.92 | 10.53 | 12.21 | 17.16 | 21.39 | 22.79 | 25.90 | 34.40 | 18.51 |
| — | -31.7% | -8.1% | -4.6% | -15.1% | -9.6% | -28.5% | -12.5% | -6.4% | -13.7% | -5.6% | -36.7% | -48.9% | -53.8% | -52.9% | -50.1% | +15.5% | +18.0% | -3.1% | +72.0% | +31.0% | |
| Quick Ratio | 9.07 | 5.61 | 7.58 | 9.07 | 8.68 | 8.22 | 8.25 | 9.51 | 10.23 | 9.09 | 11.53 | 10.87 | 10.92 | 10.53 | 12.21 | 17.16 | 21.39 | 22.79 | 25.90 | 34.40 | 18.51 |
| — | -31.7% | -8.1% | -4.6% | -15.1% | -9.6% | -28.5% | -12.5% | -6.4% | -13.7% | -5.6% | -36.7% | -48.9% | -53.8% | -52.9% | -50.1% | +15.5% | +18.0% | -3.1% | +72.0% | +31.0% | |
| Interest Coverage | 0.84 | 3.29 | -1.53 | 3.52 | 1.67 | -0.97 | -1.18 | -0.25 | -1.13 | -3.26 | -5.96 | -7.02 | -7.42 | -8.14 | -9.21 | -5.21 | -4.46 | -4.55 | -6.47 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ANAB stock.
AnaptysBio, Inc.'s current P/E is -110.4x. The average P/E over the last 3 quarters is 6.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
AnaptysBio, Inc.'s current operating margin is 20.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking AnaptysBio, Inc.'s business trajectory between earnings reports.